SEC Tracker
Get the app
DFTX · XBRL financial data

Definium Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (DFTX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development1312*12151722*23303134*4149
General and administrative811*1010811*9111514*1826
Total operating expenses2222*22242532*32414648*5975
Operating income (loss)(22)(22)*(22)(24)(25)(32)*(32)(41)(46)(48)*(59)(75)
Interest expense00*0011*1211*11
Other income (expense)4(2)*(32)1911(2)*9(2)(22)(3)*(18)(84)
Income tax expense (benefit)—————————year only——
Net income (loss)(18)(24)*(54)(6)(14)(35)*(23)(43)(67)(50)*(77)(159)
Earnings per share, basic USD per share(0.45)(0.59)*(1.14)(0.08)(0.18)—(0.27)(0.50)(0.78)(0.50)*(0.71)(1.44)
Earnings per share, diluted USD per share(0.45)(0.59)*(1.14)(0.26)(0.27)—(0.35)(0.50)(0.78)(0.51)*(0.71)(1.44)
Weighted average shares, basic millions of shares4040*48727884*858586101*109111
Weighted average shares, diluted millions of shares4040*48758078*87858699*109111

Balance sheet

CSV

Fiscal quarters (DFTX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents118100252243295274833320258263655
Short-term investments—————0130150189154111429
Prepaid and other current assets243548967878
Total current assets1201042552482992822221892164193811,092
Right-of-use asset———————1————
Goodwill202020202020202020202020
Total assets1421252762683203022752652374404011,113
Accounts payable848322248577
Accrued liabilities1012108913111519202537
Total current liabilities3132654233393038656781157
Long-term debt141414242422224140414136
Total liabilities4646796658615380106108122194
Accumulated deficit(266)(290)(345)(350)(364)(399)(422)(465)(532)(583)(660)(819)
Total stockholders' equity9678196202262241223185131332279919
Total liabilities and equity1421252762683203022752652374404011,113
Common shares outstanding (cover page) millions of shares404172727375767699100109134

Cash flows

CSV

Fiscal quarters (DFTX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(18)(24)*(54)(6)(14)(35)*(23)(43)(67)(50)*(77)(159)
Net cash from operating activities(17)*(21)*(17)(20)*(17)*(25)*(29)(30)*(30)*(43)*(43)(53)*
Net cash from investing activities——00*0*0*(162)(40)*15*35*42(317)*
Proceeds from issuing common stock3*3*——0*0*——0*0*——
Net cash from financing activities17*3*16911*69*4*120*1*246*5762*
Net change in cash1*(18)*153(9)*52*(22)*(191)(49)*(13)*238*5393*

Compare with peers

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Definium Therapeutics655not reported(53)*134.4M20.5 quarters 10-QJun 30, 2026
Myriad Genetics115191(8.3)*95.6M13.9 quarters 10-QJun 30, 2026
Kura Oncology7021(63)*89.0M8.3 quarters 10-QJun 30, 2026
KalVista Pharmaceuticals21441(14)53.2M19.7 quarters 10-QMar 31, 2026
Arbutus Biopharma191(6)*197.8M15.4 quarters 10-QJun 30, 2026
Arvinas880.5(10)*65.5M13.0 quarters 10-QSep 30, 2026
aTYR PHARMA16not reported(9.4)*98.1M6.1 quarters 10-QJun 30, 2026
Zevra Therapeutics1223810*59.5M— 10-QSep 30, 2026
Theravance Biopharma22021(7)*51.9M55.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.